About Impetis
Impetis is a company based in Mumbai (India) founded in 2016. It operates as a B2B. The company has 2 employees as of March 31, 2023. Impetis offers products and services including Adenosine Receptor Antagonists, JAK Inhibitors, BTK Inhibitors, Glucokinase Receptor Activator, and Early Stage Programs. Impetis operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Horizon Therapeutics and Forge Biologics, among others.
- Headquarter Mumbai, India
- Employees 2 as on 31 Mar, 2023
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Impetis Biosciences Limited
- Date of Incorporation 29 May, 2017
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$1.09 M (USD)2031.1as on Mar 31, 2023
-
Net Profit
$646.89 K (USD)465.68as on Mar 31, 2023
-
EBITDA
$879.43 K (USD)1384.09as on Mar 31, 2023
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
2
as on Mar 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Impetis
Impetis offers a comprehensive portfolio of products and services, including Adenosine Receptor Antagonists, JAK Inhibitors, BTK Inhibitors, Glucokinase Receptor Activator, and Early Stage Programs.
Inhibitor targeting auto-immune and inflammatory diseases in preclinical stage.
Therapy for auto-immune conditions through immune response modulation.
Treatment option for inflammatory diseases and oncology applications.
Activator for potential metabolic and inflammatory disorder management.
Preclinical initiatives for various therapeutic indications in healthcare.
Funding Insights of Impetis
Detailed funding history for Impetis
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Impetis
Investment portfolio details for Impetis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Impetis
Detailed financials for Impetis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Impetis Comparisons
Peer comparison for Impetis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Impetis
Impetis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Horizon Therapeutics and Forge Biologics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
Detailed competitors of Impetis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Impetis
Complete news archive for Impetis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Impetis
Impetis was founded in 2016.
Impetis is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
As of Mar 31, 2023, the latest employee count at Impetis is 2.
Annual revenue of Impetis is $1.09M as on Mar 31, 2023.
Impetis Biosciences focuses on discovering and developing innovative drug candidates, including inhibitors and activators, for treating auto-immune, inflammatory diseases, and immuno-oncology conditions. The company advances these assets through preclinical programs and seeks collaborations with partners to bring treatments to patients with limited options. Founded in 2017, it operates from Mumbai, India, aiming to transform lives by addressing unmet medical needs in healthcare.
Impetis offers Adenosine Receptor Antagonists, JAK Inhibitors, BTK Inhibitors, Glucokinase Receptor Activator, and Early Stage Programs.